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Abstract
Background: We have recently demonstrated that all-trans-retinoic acid (ATRA) and 9-cis-
retinoic acid (9-cis RA) promote IL-4, IL-5 and IL-13 synthesis, while decreasing IFN-J and TNF-D
expression by activated human T cells and reduces the synthesis of IL-12p70 from accessory cells.
Here, we have demonstrated that the observed effects using ATRA and 9-cis RA are shared with
the clinically useful RAR ligand, 13-cis retinoic acid (13-cis RA), and the retinoic acid receptor-D
(RAR-D)-selective agonist, AM580 but not with the RAR-E/J ligand, 4-hydroxyphenylretinamide (4-
HPR).
Results: The increase in type 2 cytokine production by these retinoids correlated with the
expression of the T cell activation markers, CD69 and CD38. The RAR-D-selective agonist, AM580
recapitulated all of the T cell activation and type 2 cytokine-inducing effects of ATRA and 9-cis-RA,
while the RAR-D-selective antagonist, RO 41–5253, inhibited these effects.
Conclusion: These results strongly support a role for RAR-D engagement in the regulation of
genes and proteins involved with human T cell activation and type 2 cytokine production.
Background
Retinoids are natural or synthetic vitamin A (VA) deriva-
tives. Retinoic acid (RA) is present in human plasma at a
concentration of around 10–20 nM mainly in two stereoi-
someric forms, all-trans-RA (ATRA, ~75%) and 13-cis-RA
(~25%) [1]. The concentration of ATRA in most rat and
human tissues is higher than the plasma concentration
[2,3]. The plasma and tissue concentrations of 9-cis RA are
at or below the limits of detection of modern methods of
analysis [2,3] and very little bioconversion/isomerization
to 9-cis RA occurs after pharmacological administration of
ATRA or 13-cis RA. Recently, two other retinoic acid recep-
tor interacting retinoids, all-trans-13,14-dihydroretinoic
acid and beta -apo-14'-carotenal, have been identified in
tissue [4,5]
Retinoids regulate the expression of more than 300 differ-
ent genes through various mechanisms [6]. Predominant
among the mechanisms is the ability of retinoids such as
ATRA (Tretinoin®) and 9-cis-RA (Panretin®) to bind to at
least two classes of nuclear receptors, RA receptors (RARs)
and/or retinoid × receptors (RXRs) [7]. ATRA binds exclu-
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sively to RARs while 9-cis-RA binds to both RARs and
RXRs. The affinity of 9-cis-RA for RXRs is about 5–10 fold
higher and its transactivating potential is approximately
10–30 times higher than for RARs [8]. Moreover, ATRA is
likely to exhibit some RXR-stimulating activity in vitro due
to its conversion to 9-cis-RA [9]. The low plasma and tis-
sue levels of 9-cis-RA have lead to a search for other possi-
ble endogenous ligands for RXRs. To date, phytanic acid
[10] docosahexaenoic acid [11] and other unsaturated
fatty acids [12] have been proposed as additional/alterna-
tive ligands for RXRs; whereas, beta -apo-14'-carotenal
may be a naturally-generated RXR antagonist [5]
When bound with ligand, RAR/RXR heterodimers or RXR
homodimers transactivate specific cis-elements of target
genes (known as retinoic acid response elements (RAREs)
or retinoid × response elements (RXREs). Each RAR or
RXR has three major isoforms (D, E, or J) which are tissue
selective and developmentally regulated [7]. Individual
isoforms of RARs and RXRs may interact with distinct
RAREs or RXREs to regulate gene expression. Alternately
RARs and RXRs may differentially interact with other tran-
scription factors such as the nuclear receptor for 1,25
(OH)2 vitamin D3 (Vit D3), AP-1, CEBPB/NF-IL6 and the
silencing mediator of retinoid and thyroid hormone
(SMRT) to stimulate or repress gene transcription [13].
These data suggest that individual RAR and RXR isoforms
may have unique functions.
The role of specific retinoid receptors in the differential
regulation of immune responses is an area of active inter-
est. This is particularly true for T cell-mediated immunity.
The role of RAR-J in the induction and RAR-D/RXR-J in
the inhibition of thymocyte apoptosis has been exten-
sively characterized [14]. However, the role of specific
retinoic acid receptors in peripheral T cell function is
largely unknown. Several groups have demonstrated that
expression of RAR-D RNA and protein increases after T cell
activation [15,16]. In contrast, RAR-J and RXR-D expres-
sion decrease during T cell activation [17,18]. While the
precise biological role of these differentially expressed
retinoic acid receptor isoforms by activated human
peripheral T cells is currently unknown, several research
groups have explored the role of different retinoid recep-
tors in the regulation of T cell-derived cytokines such as
interferon-J (IFN-J) and interleukin-4 (IL-4). IFN-J and
IL-4 are produced in a reciprocal fashion by T cells and are
associated with T helper type 1 (Th1) and Th2-associated
responses, respectively.
Reports on the effects of specific retinoic acid receptors on
IFN-J production by T cells appear contradictory. In one
study, ATRA significantly downregulated IFN-J promoter
activity in RAR-D-transfected Jurkat cells [19] via interac-
tion with a negative response element putatively identi-
fied as USF1. Other reports described the ability of the
RAR-D-selective retinoid, Am80 [20] to inhibit IFN-J from
antigen-stimulated mouse T cells [21,22]. However, a
another report demonstrated no effect of Am80 on IFN-J
production by murine Th1 clones [23], while the pan-
RAR/RAR-E-selective retinoid, CH55 [24], was more
potent than either ATRA or 9-cis RA in inhibiting IFN-J
production from murine Th1 clones [25]. Finally, in vitro,
antigen-specific, IFN-g synthesis was inhibited by 9-cis-RA
and a RXR-selective retinoid but not by ATRA or a RAR-
selective retinoid [26]. In murine memory T cells, 9-cis
and a RXR-selective retinoid inhibited IL-4, IL-5 and IFN-
J production [27] Finally, a single study showed that 9-cis-
RA reduced IL-13 mRNA from ex-vivo antigen-stimulated
murine T cells [28].
A number of in vivo studies conducted to determine the
role (s) of specific retinoic acid receptors on Th1- or Th2-
mediated pathologies have also yielded conflicting
results. Systemic administration of RAR-D-selective retin-
oids have been shown to inhibit Th1-associated immune
responses such as delayed type hypersensitivity (DTH)
[21,29], the progression of experimental arthritis [23] and
skin allograft rejection [30]. In contrast, systematic
administration of an RXR antagonist decreased produc-
tion of IL-4, IL-10, and IL-13, and increased IFN-J produc-
tion and increased inflammation in a mouse model of
allergic lung inflammation [31]. Additionally, mice
expressing a hypomorphic mutation in the RXR-D gene
have an exaggerated Th1 immune response but a relatively
normal TH2 response [32]. Finally, mice engineered to
express reduced amounts of RXR-D in T cells showed no
difference in polyclonally-stimulated IL-5, IL-5 and IFN-g
production, ex vivo naïve to memory Th1 or TH2 develop-
ment and only a small increase in IL5 and a small decrease
in IFN-J production from memory cell [27].
Despite their potential clinical utility, a very limited
number of studies have examined the comparative ability
of retinoids such as ATRA, 9-cis RA, 13-cis RA, and 4-HPR
to modulate Th1 cell or Th2 cell differentiation. One in
vitro study indicated that 13-cis, ATRA, and 9-cis-RA were
equipotent in inhibiting IFN-J production from murine
Th1 cells [25]. Similarly, our own previous work sug-
gested that ATRA and 9-cis RA were equipotent in modu-
lating Th2-associated responses in human T cells [33]. An
additional report demonstrated that 13-cis RA and 4-
hydroxyphenylretinamide (4-HPR), a synthetic retinoid,
equally inhibited the progression of experimental autoim-
mune encephalomyelitis (EAE) in mice [34]. Previous
studies have demonstrated that the balance of Th1 to Th2
T cells plays a role in the progression of this disease.
Although this limited data would suggest that ATRA, 9-cis
RA 13-cis RA and 4-HPR may be equal in their Th2-induc-
ing activity, their potential differences in receptor selectiv-
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ity and the differential ability of receptor-selective
retinoids to modulate Th2-development in murine mod-
els, indicate that these retinoids may differ in their ability
to influence human Th1/Th2 development. In the current
report, we have examined the comparative ability of
ATRA, 9-cis RA 13-cis RA and 4-HPR as well as RAR-D-
selective agonists and antagonists to modulate T cell acti-
vation as well as promotion of a Th2-associated cytokine
response. Our data supports a role for RAR-D engagement
in T cell activation and the preferential expression of Th2-
associated cytokines
Results
Differential expression of type 1- and type-2-associated 
cytokines and cell surface activation markers by various 
retinoid compounds
Initial studies focused on comparison between the retin-
oid compounds, ATRA and 9-cis-RA, and the clinically uti-
lized retinoids, 13-cis-RA and 4-HPR. The results shown
in Table 1 and Figure 1 demonstrate the ability of the
retinoids, ATRA, 9-cis-RA and 13-cis-RA, to significantly
stimulate production of IL-4 from anti-CD3 mAb-stimu-
lated PBMC in a dose-dependent fashion. While ATRA
and 9-cis-RA were equipotent in this regard, 13-cis-RA was
about 10 fold less active. 4-HPR was slightly inhibitory at
low doses and stimulatory only at the highest dose (1
PM). Similarly, the effects of retinoids on IL-5 (Table 1
and Figure 1), and IL-13 (data not shown) production
were remarkably similar to that of IL-4. They had no effect
on IL-10 (data not shown). For Th1-associated cytokines,
9-cis-RA was approximately 10 times more effective than
ATRA at inhibiting IFN-J production (Table 2 and Figure
2). 13-cis-RA and ATRA were equipotent and 4-HPR was
approximately 1,000 fold less effective. For IL-12p70,
ATRA was more effective than 9-cis and 13-cis RA at 1 nM
but was equipotent at 10–1000 nM.
Given the differences in the ability of these retinoids to
modulate cytokine production, we next examined
whether the ability of retinoids to induce type 2 cytokine
production is related to their ability to induce T cell acti-
vation. To this end, we examined the expression of the T
cell activation markers, CD25, CD38, and CD69. CD69 is
an early marker of T cell activation and CD38 expression
is induced after T cell activation and is reportedly under
the direct control of RAR-D [35]. The results in Table 3
demonstrate that ATRA, 9-cis-RA, and 13-cis-RA and to a
lesser extent, 4-HPR, consistently increased the expression
of CD69 and CD38. These increases were dose-dependent
with following degrees of potency and efficacy observed:
9-cis-RA > ATRA, 13-cis-RA > > 4-HPR. All of the retinoids
failed to increase CD25 expression above control at any
concentration tested (data not shown). CD25 is part of
the IL-2 receptor complex and is typically expressed as an
intermediate marker of T cell activation. The relationship
between type 2 cytokine expression and CD upregulation
on T cells was further examined by linear regression. As
shown in Figures 3A and 3B, the expression of IL-5 was
highly correlated (p < 0.0001) with CD38 and CD69
expression using the mean fold change of three experi-
ments and the four retinoids at the doses indicated in
Tables 1 and 2. A similar degree of correlation between the
expression of these CD markers and IL-4 levels was also
observed in these studies (data not shown).
Table 1: ATRA, 9-cis RA and 13-cis RA significantly increase the 
production of Th2-associated cytokines from anti-CD3-
stimulated PBMC cultures in a dose-dependent fashion.
IL-4 Fold vs Control ± SE (n = 3)
Doses (nM)
1 10 100 1000
Retinoid
ATRA 1.7 ± 0.55 2.4 ± 0.40 2.5 ± 0.48 2.7 ± 0.64
9-cis-RA 1.2 ± 0.05 2.3 ± 0.38 2.3 ± 0.57 2.4 ± 0.65
13-cis-RA 1.2 ± 0.13 1.7 ± 0.25 1.7 ± 0.42 1.8 ± 0.30
4-HPR 0.7 ± 0.11 0.8 ± 0.18 1.0 ± 0.13 1.6 ± 0.45
2-way ANOVA
Dose p = 0.02
Retinoid p = 0.0003
Tukey Kramer
Dose p < 0.05 1 nM vs 100 nM
1 nM vs 1000 nM
Retinoid p < 0.01 4-HPR vs ATRA
p < 0.01 4-HPR vs 9-cis-RA
IL-5 Fold vs Control ± SE (n = 3)
Doses (nM)
1 10 100 1000
Retinoid
ATRA 1.9 ± 0.41 2.4 ± 1.0 2.8 ± 1.1 3.1 ± 1.3
9-cis-RA 1.0 ± 0.10 2.4 ± 1.0 3.0 ± 0.85 3.0 ± 1.1
13-cis-RA 1.3 ± 0.31 1.6 ± 0.45 1.9 ± 0.67 2.0 ± 0.84
4-HPR 0.8 ± 0.05 0.9 ± 0.26 1.2 ± 0.40 1.5 ± 0.30
2-way ANOVA
Dose p = 0.07
Retinoid p = 0.005
Tukey Kramer
Retinoid p < 0.05 4-HPR vs 9-cis RA
p < 0.01 4-HPR vs ATRA
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Differential regulation of T cell activation markers and 
type 1- and type-2-associated cytokines by an RAR-D 
agonist and a RAR-D antagonist
Based on the differential ability of 13-cis RA and 4-HPR to
modify Th2-associated cytokine production and the high
degree of correlation with expression of CD38, a RAR-D-
induced cell surface marker, we hypothesized that RAR-D
may be involved in the process of type 2 differentiation.
However, the use of these retinoids could not exclude a
role for other RAR and RXR receptors due to possible
inter-conversion between the various retinoids. Therefore,
a highly selective RARD agonist and antagonist were
examined and compared with ATRA for their ability to
induce type 2 cytokine production. The results in Figure 4
demonstrate that both ATRA and the RARD agonist,
AM580, significantly induced IL-4, IL-5 and IL-13 synthe-
sis above vehicle control. They had no effect on IL-10
(data not shown). In contrast, the RAR-D selective antago-
nist, Ro 41-5254, decreased IL-4, IL-5 and IL-13 synthesis
to approximately 60% of control values; although these
differences were only marginally significant (p = 0.11,
0.13 and 0.13 respectively). This is most likely due to the
variability inherent in using PBMCs from different human
donors. Similar to the previous ATRA results, AM580
exhibited a significant inhibitory effect on both IFN-J and
IL-12 synthesis using anti-CD3-stimulated PBMC (Figure
5). The RAR-D-antagonist exerted little to no effect on
either type 1-associated cytokine production suggesting
the effects of this antagonist within the culture system is
specific and direct for type 2 cytokines. While not shown,
both ATRA and AM580 exhibited a similar potency and
efficacy in our culture systems. These retinoid-induced
effects induced similar effects on type 2 cytokine mRNA
expression (Figure 6).
For the sake of clarity and cohesion with regard to retinoid
effects on Th1 and Th2 -associated cytokine expression
and production, we have focused mainly on our PBMC
data in this manuscript; however, IL-12 is likely produced
by accessory cells such as monocyte/macrophages in our
system. However, we have demonstrated similar enhance-
ment of IL-4, IL-5, and IL-13 levels using AM580 and
ATRA agonists and the RO 41–5254 antagonist within
anti-CD3 and anti-CD28-stimulated highly purified T cell
cultures (Table 4A). The statistical trends were weaker
than PBMCs because of the high level of donor to donor
variation in production of these cytokines. The lack of an
effect on IFN-J production probably reflects the influence
of retinoids on IL-12 and other cytokines. Interestingly,
IL-10 production was inhibited by ATRA and Am-580 as
well as the RAR-D antagonist. Similar to the data reported
for PBMCs, the effects of the retinoids on IL-4, IL-5 and IL-
13 were similar to their effects on CD38 and CD69 expres-
sion (Table 4B). These results suggest that endogenous
retinoids have multiple actions and may play an influen-
tial role in T cell differentiation and cytokine expression.
These data on RAR-D agonist and antagonist cannot
exclude a role for other RAR receptors in Th2 develop-
ment. To this end we have also examined the comparative
ability of the RAR-J agonist SR11254 and RAR- E/J ago-
nist, Ro 44–5743, to stimulate Th2 cytokine syntheses in
CD3,-stimulated PBMC and CD3,- and CD28-stimulated
T cells. Compared to ATRA and AM580, these agonists
were significantly less effective in stimulating IL-5 synthe-
sis (data not shown).
Similar to the data on ATRA and 9-cis-RA shown in Table
3, AM580 increased the MCN and the percentage of T cells
expressing CD69 (Figure 7A) and CD38 (Figure 7B) in
anti-CD3, activated PBMC cultures. We typically observed
a 2–3 fold increase in the MCN of CD69 and CD38 using
these retinoids. Conversely, the RAR-D-selective antago-
nist inhibited the expression of these molecules (Figure
7A and 7B). Thus, it would appear that ATRA and the RAR-
D selective retinoid, AM580, induce similar and compara-
ble activation of human T cells in our culture system. In
addition, we have also examined the comparative ability
of the RAR-J agonist SR11254 and RAR-E/J(agonist, Ro
44–5743, to stimulate CD38 and CD69 expression in
anti-CD3,- or anti-CD3/anti-CD28-stimulated PBMC and
T cells. Compared to ATRA and AM580, these agonists
The effects of various clinically-utilized retinoid compounds on Th2-as ociated cytokine production by anti-CD3e-acti-vat d PBMCsFigure 1
The effects of various clinically-utilized retinoid com-
pounds on Th2-associated cytokine production by 
anti-CD3e-activated PBMCs. Supernatants of anti-CD3e-
activated PBMCs treated with EtOH or 10-9 to 10-6 M ATRA 
(), 9-cis-RA (&#x25A1;), 13-cis-RA (), or 4-HPR () for 48 
h were examined for IL-4 or IL-5. The values shown repre-
sent the average fold change obtained from 4 donors.
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were significantly less effective at inducing the expression
of CD38 and CD69 (data not shown).
Lack of involvement of liganded RXR in ATRA- and RAR-
D-mediated cytokine production
Because ATRA and 9-cis RA were relatively equipotent in
their effects on IL-4, IL-5 and IL-13 synthesis, we hypoth-
esized that liganded RXRs may be only minimally
involved in the type 2 cytokine-inducing effects of ATRA.
Previous studies that examined the ability of certain retin-
oids to inhibit IL-12p70 synthesis and to induce thymo-
cyte apoptosis, found 9-cis-RA to be at least 10 times more
potent than ATRA on a molar basis (5, 23). The authors of
these studies have suggested that given the enhanced
effects of 9-cis-RA that RXRs were involved in this process
[14,36]. To directly address this question, we have exam-
ined the ability of an RXR-selective retinoid, SR11345, in
conjunction with ATRA or the RAR-D-selective retinoid,
AM580 to modulate type 1 and 2 cytokine production in
two independent human donors. Previous reports have
demonstrated a molecular cooperative or obligate interac-
tions of liganded RARs receptors with liganded RXRs by
Table 2: ATRA, 9-cis RA and 13-cis RA significantly decrease the production ofTh1-associated cytokines from anti-CD3-stimulated 
PBMC cultures in a dose-dependent fashion.
IFN-J Fold vs Control ± SE (n = 3)
Doses (nM)
1 10 100 1000
Retinoid
ATRA 0.63 ± 0.04 0.61 ± 0.05 0.43 ± 0.13 0.38 ± 0.10
9-cis-RA 0.76 ± 0.06 0.38 ± 0.09 0.32 ± 0.06 0.30 ± 0.05
13-cis-RA 0.64 ± 0.11 0.59 ± 0.04 0.53 ± 0.04 0.47 ± 0.09
4-HPR 0.83 ± 0.11 0.75 ± 0.07 0.73 ± 0.02 0.65 ± 0.03
2-way ANOVA
Dose p = 0.0001
Retinoid p < 0.0001
Tukey Kramer
Dose p < 0.01 1 nM vs 100 nM
1 nM vs 1000 nM
Retinoid p < 0.01 4-HPR vs ATRA
4-HPR vs 9-cis RA
4-HPR vs 13-cis RA
IL-12p70 Fold vs Control ± SE (n = 3)
Dose (nM)
1 10 100 1000
Retinoid
ATRA 0.57 ± 0.18 0.40 ± 0.11 0.36 ± 0.13 0.27 ± 0.12
9-cis-RA 1.0 ± 0.12 0.39 ± 0.07 0.25 ± 0.19 0.21 ± 0.09
13-cis-RA 1.1 ± 0.29 0.61 ± 0.20 0.42 ± 0.14 0.41 ± 0.09
4-HPR 1.2 ± 0.47 1.2 ± 0.41 0.94 ± 0.26 0.84 ± 0.16
2-way ANOVA
Dose p = 0.004
Retinoid p = 0.0007
Tukey Kramer
Dose p < 0.05 1 nM vs 100 nM
p < 0.01 1 nM vs 1000 nM
Retinoid p < 0.01 4-HPR vs ATRA
4-HPR vs 9-cis-RA
p < 0.01 4-HPR vs 13-cis-RA
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using combinations of RAR- and RXR-selective ligands
[14,37,38]. The results in Figure 8 demonstrate the ability
of the RXR agonist, SR11345, to inhibit IL-12p70 and
IFN-J synthesis (Panel A), but with little to no additional
activity on type 2- cytokine synthesis alone or in combina-
tion with RARD agonists (Panel B). Similar results were
obtained for IL-4 and IL-5 levels using purified human T
cells (data not shown). These results and those in Table 2,
suggest that liganded RXRs appear to exert inhibitory
effects on type 1 cytokine production alone but are less
efficacious than RARD agonists and do not appear to be
playing a role in type 2 cytokine responses.
Discussion
Several clinically useful retinoids including 13-cis RA
(Isotretinoin or Accutane®), and 4-HPR (fenretinide), dif-
fer from ATRA (Tretinoin®) and 9-cis RA (Panretin®) in
their biological activity and/or toxicity. These differences
in activity are thought to be primarily due to their differ-
ential ability to bind RAR or RXR and their subsequent
ability to induce gene transactivation and/or transrepres-
sion. 13-cis-RA, in conjunction with IFN-J is an effective
chemotherapeutic agent for squamous cell carcinoma of
the skin and cervix and is useful in the chemoprevention
of secondary head and neck tumors [13]. The RAR and
RXR binding and transactivating ability of 13-cis RA are
controversial. Several studies have suggested that 13-cis
RA possesses a moderate affinity for RARs, especially RAR-
D, but possesses little to no affinity or activating potential
for RXRs [8,39-41]. However, like ATRA and 9-cis RA, in
vitro conversion of 13-cis RA to other bioactive retinoids
has been demonstrated [9]. 4-HPR, a synthetic retinoid,
exerts potent chemopreventive action in animal models of
carcinogenesis; however, its effectiveness in humans
remains to be determined [42]. Like 13-cis RA, the ability
of 4-HPR to bind and transactivate RARs or RXRs is a mat-
ter of controversy [43-46]. In studies examining 4-HPR
interactions with these receptors, 4-HPR appears to bind
to and transactivate RAR-E and RAR-J but not RAR-D and
RXRs [47]. 4-HPR does not undergo appreciable transfor-
mation to retinoids such as ATRA [42].
Several lines of evidence presented within the current
report suggest that RAR-D-selective retinoids can recapitu-
late all of the previously observed effects of retinoids on
the differentiation process of Th2 cells: (1) ATRA and 13-
cis RA, which operate mainly via RARs, induces type 2
cytokine expression; (2) 4-HPR, a potential transactivator
of RAR-E/J(but not RAR-D or RXRs, exerts minimal effects
on expression of IL-4, IL-5, and IL-13; (3) TTNPB, a selec-
tive activator of RARs, is capable of inducing cytokine
expression similar to ATRA, 9-cis and 13-cis RA (H. Daw-
son and D.D. Taub, unpublished observation); (4)
AM580 stimulates type 2 cytokine synthesis to the same
degree as ATRA; (5) the RAR- D-selective antagonist, Ro
41–5254, inhibits the expression of Th2-like cytokines;
and (6) the use of an RXR-selective agonist alone or in
combination with ATRA or AM580, exerts no effect on
type 2 cytokine expression. Together, these results suggest
that in vitro human Th2 cell differentiation is predomi-
nantly regulated by retinoids through the RAR-D-depend-
ent signaling pathway.
There are a very limited number of studies that have exam-
ined the role of specific RARs in the regulation of IL-4 pro-
duction by rodent and human T cells. In one study, the
pan RAR selective retinoid, TTNPB, was active, but far less
effective, than either ATRA or 9-cis RA in inducing IL-4
synthesis from antigen-stimulated murine T cells [48].
However, the role of the RAR receptor in this regulation is
unclear because the RAR-D-selective retinoid, Am-80,
failed to affect IL-4 production by antigen-stimulated
murine Th2 clones [23] or antigen-stimulated murine T
cells [21] and in vitro antigen-stimulated murine T cell IL-
4 synthesis was stimulated by 9-cis-RA and an RXR-selec-
tive retinoid, but not by ATRA or an RAR-selective retinoid
[49]. The effects of receptor-selective retinoids on the pro-
duction of other Th2 cytokines were not examined in
these studies. The current report has directly demon-
strated an RAR-D-specific effect on type 2 cytokine expres-
The effects of various clinically-utilized retinoid compounds on Th1-as ociated cytokine production by anti-CD3e-acti-vat d PBMCsFigure 2
The effects of various clinically-utilized retinoid com-
pounds on Th1-associated cytokine production by 
anti-CD3e-activated PBMCs. Supernatants of anti-CD3e-
activated PBMCs treated with EtOH or 10-9 to 10-6 M ATRA 
(), 9-cis-RA (&#x25A1;), 13-cis-RA (), or 4-HPR () for 48 
h were examined for IFN-J or IL-12 protein levels by ELISA 
analysis. The values shown represent the average fold change 
obtained from 4 donors.
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sion on human PBMC and T cells in the absence of
accessory cells.
Our current data appear to contradict findings of two pub-
lished studies where 13-cis, ATRA, and 9-cis-RA were all
equipotent in inhibiting IFN-J production from rodent
Th1 cells [25]. In addition, in vitro antigen-stimulated
murine T cell IL-4 synthesis was stimulated by 9-cis-RA
and an RXR-selective retinoid, but not by ATRA or an RAR-
selective retinoid [49]. Our data regarding RAR-D also dif-
fer with those of another report where an experimental
RAR-D-selective retinoid failed to affect the production of
IFN-J by Th1 clones and IL-4 by mouse Th2 T cell clones
[23] or antigen-stimulated naïve T cells [21]. In a more
recent study, ATRA, 9-cis-RA, and an RAR agonist were
found to be potent inducers of cellular proliferation and
IL-2 production by enriched human T cells [50]. These
effects were found to occur predominantly with RAR ago-
nists and only marginal effects being observed through
the use of RXR agonists. More interestingly, while we have
Table 3: ATRA, 9-cis RA and 13-cis RA significantly increase the expression of CD38 and CD69 on T cells in anti-CD3-stimulated 
PBMC cultures in a dose-dependentfashion.
CD38 MCN Fold vs Control ± SE (n = 3)
Dose (nM)
1 10 100 1000
Retinoid
ATRA 1.49 ± 0.07 1.60 ± 0.05 1.63 ± 0.07 1.67 ± 0.05
9-cis-RA 1.11 ± 0.02 1.43 ± 0.02 1.77 ± 0.08 1.93 ± 0.02
13-cis-RA 1.28 ± 0.06 1.50 ± 0.06 1.68 ± 0.10 1.71 ± 0.08
4-HPR 1.11 ± 0.02 1.15 ± 0.02 1.20 ± 0.02 1.66 ± 0.19
2-way ANOVA
Dose p = 0.0001
Retinoid p < 0.0001
Tukey Kramer
Dose p < 0.01 1 nM vs 10 nM
1 nM vs 100 nM
1 nM vs 1000 nM
Retinoid p < 0.01 4-HPR vs ATRA
4-HPR vs 9-cis RA
4-HPR vs 13-cis RA
CD69 MCN Fold vs Control ± SE (n = 3)
Dose (nM)
1 10 100 1000
Retinoid
ATRA 1.29 ± 11.0 1.27 ± 10.5 1.40 ± 0.14 1.46 ± 0.15
9-cis-RA 1.07 ± 3.4 1.27 ± 8.2 1.59 ± 0.16 1.64 ± 0.15
13-cis-RA 0.99 ± 4.0 1.12 ± 3.4 1.24 ± 0.08 1.33 ± 0.11
4-HPR 0.85 ± 6.2 0.86 ± 3.3 0.94 ± 0.04 1.08 ± 0.04
2-way ANOVA
Dose p = 0.0001
Retinoid p < 0.0001
Tukey Kramer
Dose p < 0.01 1 nM vs 100 nM
1 nM vs 1000 nM
Retinoid p < 0.01 4-HPR vs ATRA
4-HPR vs 9-cis-RA
4-HPR vs 13-cis-RA
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also observed increased activation and proliferation by
human T cells upon culture with RAR agonists, no signif-
icant changes in the production of IL-2 (another type 1
cytokine) were observed post RAR agonist treatment in
our hands (data not shown). In addition to authentic spe-
cies and differences in biological activities of synthetic
retinoid putatively acting through the same receptor, sim-
ple differences between cell purification procedures, cul-
ture conditions, activation regiment, age of donors,
memory/naïve and CD4/CD8 ratios, nutritional status,
species and the donor population being examined may
account for differences between studies. However, we
have found similar results with ATRA, 9-cis-RA and
Am580 when using pig PBMCs (H. Dawson, unpub-
lished).
One potential limitation of our study is the relatively
weak antagonistic activity demonstrated by the RAR-
antagonist, Ro 41–5254. This antagonist binds to RAR-D
with four and two times less affinity than ATRA and
AM580, respectively [51]. Previous studies have effectively
utilized this compound only at a molar ratio of 1000:1 to
100:1 of antagonist to agonist [35,51]. Using the inhibi-
tion of induction of CD38 antigen expression by ATRA as
a bioassay for RAR-D-mediated activation, this compound
exhibited a 10%, 40%, and 80% inhibitory activity at a
molar ratio of 10:1, 100:1, and 1,000:1, respectively (data
not shown). Using a 100:1 molar ratio of antagonist to
agonist (AM580 or ATRA), we have also observed a 60–
70% reduction in the synthesis of Th2-associated
cytokines by CD3-stimulated PBMC (data not shown).
There is recent evidence that Ro 41–5254 is a peroxisome
proliferator-activated receptor-gamma (PPAR-J) agonist
[52]. PPAR-J agonists can inhibit Th1 and Th2 responses.
Although Ro 41–5254 exhibited little activity in this
regard in our system, we cannot rule out interactions
between the retinoid and PPAR pathways. Another limita-
tion is that we cannot rule out the possibility that there
was sufficient endogenous RXR-active retinoids in this sys-
tem to permit RAR- and liganded RXR-mediated nuclear
transactivation. However, as normal serum (similar to the
serum utilized in our culture system) contains negligible
concentrations of 9-cis RA but appreciable quantities of
other retinoids such as ATRA (10 to 100 nM) and 13-cis
RA (2.5 to 25 nM), we feel that this is unlikely.
RAR-D has at least two isoforms, RAR-D-1 and RAR-D-2,
which arise as a consequence of differential splicing. Anal-
ysis of transgenic mice, which under- or overexpress RAR-
D-1, has revealed limited effects on the development, phe-
notype and/or function of the immune system [53]. Adult
mice expressing low amounts of RAR-D develop spontane-
ous T and B cell lymphomas and had very low amounts of
the RA-inducible gene, CD38, in thymus and bone mar-
row [35,54]. In vivo experiments have suggested that RAR-
D agonists may exhibit inhibitory effects on T-cell medi-
ated immunity. Systemic administration of RAR-D-selec-
tive retinoids have been shown to inhibit DTH [21,29],
the progression of experimental arthritis [23], prolong
skin allograft survival [30], and inhibit Ab production in
mice [29].
Our proposed model of the role of RAR-D in Th2 develop-
ment has parallels in other cell types. Recent studies sug-
gest that the differential engagement of individual RARs
or RXRs may regulate the process of monocyte differenti-
ation into macrophages or dendritic cells [55] and the
a
Correlation between retinoid-induced IL-5 expression and T cell-associated CD38 and CD69 expression in anti-CD3, -activated PBMCFigur  3
Correlation between retinoid-induced IL-5 expres-
sion and T cell-associated CD38 and CD69 expres-
sion in anti-CD3, -activated PBMC. IL-5 protein levels 
were quantitated by ELISA in supernatants of 48 h, anti-
CD3,-activated PBMC treated with ETOH or ATRA (), 9-
cis-RA (&#x25A1;), 13-cis-RA (), or 4-HPR (). The values 
for the level of expression (mean channel number) of CD38 
and CD69 on T cells were obtained by flow cytometry of 
cells from the same culture. Simple regression was per-
formed on these values as described in Materials and Methods. 
Data shown is average fold change calculated from three 
experiments.
%0&,PPXQRORJ\ 2008, :16 http://www.biomedcentral.com/1471-2172/9/16
Page 9 of 14
SDJHQXPEHUQRWIRUFLWDWLRQSXUSRVHV
induction or prevention of apoptosis of B cells and T cells
[14,56], as well as normal neutrophil differentiation [57].
Several recent studies have focused on the effects of recep-
tor-selective retinoids on accessory cells in the regulation
of Th1 or Th2-like cytokine production by T cells. 9-cis-RA
and the RXR-selective retinoid, LG69, have been shown to
inhibit LPS-stimulated IL-12 production from murine
macrophages more effectively than the pan RAR-selective
retinoid, TTNPB [39]. Similarly, 9-cis-RA was more effec-
tive than TTNPB in downregulating IL-12 protein synthe-
sis in LPS- or KLH-stimulated mouse macrophages [48].
More recent human studies have demonstrated a direct
effect of ATRA and RXR rexinoids on IL-2 receptor expres-
sion by human cutaneous T-cell lymphomas through RAR
and RXR receptors (45,46). Overall, the bulk of evidence
from all of these studies point to a predominant role for
liganded RXRs in these processes.
Conclusion
Our data suggest a lesser role for liganded RXRs in the
inhibition of IFN-J and IL-12 production in a mixed pop-
ulation of cells during T cell activation. A dose-response
titration of the RXR-selective retinoid showed that it was
approximately 100 fold less effective than ATRA and 9-cis-
RA and 10 times less effective than the pan RAR agonist
TTNPB in inhibiting IFN-J and IL-12 expression (H. Daw-
son and D.D. Taub, unpublished observations). These
findings are in direct contrast with a recently published
murine T cell study demonstrating that stimulation of the
RXR pathway enhances Th2 development by murine T
cells (47). While it would appear, based on the published
retinoid literature, that human and murine T cells differ-
entially respond to RAR and RXR agonists, we believe that
the inactivity of the RXR ligand in regulating the produc-
tion of Th2 cytokines by human T cells suggests only the
involvement of the RAR/RXR heterodimer and not the
RXR/RXR homodimer in Th2 cytokine induction.
Methods
Reagents
ATRA, 9-cis RA, and 13-cis RA were purchased from Sigma
(St Louis, MO), the RAR-D agonist, AM580 (Ro-40–6055)
[58], 4-HPR, and the pan RAR agonist TTNPB were pur-
chased from Biomol (Plymouth Meeting, PA). The RAR-D
antagonist, Ro 41–5253 [51], and RAR-J agonist, Ro 44–
5743, were generously provided by Michael Klaus Ph.D.
(Hoffman LaRoche, Basel) and the RXR agonist, SR11345
A RAR-D agonist specifically induces Th2-associated cytokine production by anti-CD3,-act vated PBMCFigure 4
A RAR-D agonist specifically induces Th2-associated 
cytokine production by anti-CD3,-activated PBMC. 
IL-4, IL-5, and IL-13 proteins were quantitated by ELISA in 
supernatants of 48 h, anti-CD3,-activated PBMC treated with 
EtOH, ATRA (10-7 M), the RAR-D agonist, AM580 (10-7 M), 
or an RAR- D antagonist, RO 41-5254 (10-7 M). The values 
shown represent the average obtained from 4 donors ± SEM. 
Means that express different superscripts are significantly dif-
ferent by at least p < 0.02.
A RAR-D agonist specifically inhibits Th1-associated cytokine production by anti-CD3,-activated PBMCFigure 5
A RAR-D agonist specifically inhibits Th1-associated 
cytokine production by anti-CD3,-activated PBMC. 
IFN-J (panel A) and IL-12p70 (panel B) proteins were quanti-
tated by ELISA in supernatants of 48 h, anti-CD3,-activated 
PBMC treated with control EtOH, ATRA (10-7 M), AM580 
(10-7 M), or an RAR- D antagonist, RO 41–5254 (10-7 M). The 
values shown represent the average obtained from 4 donors 
± SEM. Means that express different superscripts are signifi-
cantly different by at least p < 0.03.
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[59] and RAR-J agonist, SR11254 [60], were generously
provided by Marcia Dawson Ph.D (Medicinal Chemistry
Department, Molecular Medicine Research Institute,
Mountain View, CA). The retinoids were pre-diluted
1000X in ethanol and added to the media at 1 uL/mL. To
avoid photo and chemical isomerization, retinoid solu-
tions were overlayered with argon gas and stored at -80°C
in the dark until use.
Cell Preparation
Whole blood was acquired from healthy human volun-
teers between the ages of 21–55 years. PBMC were iso-
lated by Ficoll Paque (Amersham Pharmacia Biotech,
Piscataway, NJ) density gradient centrifugation followed
by treatment with ammonium chloride (ACK) lysis solu-
tion (Biofluids, Gaithersburg, MD) to eliminate the
remaining erythrocytes. The isolated cells were subse-
quently washed 2 times in PBS and resuspended in RPMI
1640 (Biofluids) supplemented with 10% heat-inacti-
vated FBS (Sigma), 2% heat-inactivated pooled human AB
serum (Sigma), 50:M mercaptoethanol (Gibco BRL Gaith-
ersburg, MD), 1 mM sodium pyruvate (Biofluids), 2 mM
glutamine, 1 × non-essential amino acid solution (Bioflu-
ids), 1 mg/ml gentamicin (Biowhittaker, Walkersville,
MD), 100 U/ml penicillin (Biofluids), 100:g/ml strepto-
mycin (Biofluids), and 20 mM HEPES buffer (Biofluids).
T cells were isolated by negative selection using enrich-
ment columns according to manufacturer's instructions
(R & D Systems). These cells were typically > 95% pure as
assessed by flow cytometric analysis. The contaminating
cell population was largely CD8+ and most likely were NK
cells based on their size and granularity.
Cell Culture and Harvest
PBMC (2.5 × 10 6 cells/ml) were activated with 200 ng/ml
of immobilized anti-CD3H (OKT-3, Ortho, Raritan, NJ) in
the presence or absence of 0.001 to 1:M of various retin-
oids or EtOH vehicle control for 48 h. IL-2 (Teceleukin,
Hoffman LaRoche, Nutley, NJ) at 10 U/ml or 1:g/ml of
neutralizing anti-cytokine mAb were added to the cultures
where indicated. Alternately, T cells (1.0 × 10 6 cells/ml)
were activated with 200 ng/ml of immobilized anti-CD3,
and 1:g of soluble anti-CD28 (clone 28.2, Pharmingen) or
with IL-2 at 10 U/ml where indicated. PBMC or T cells
were harvested at various time intervals after incubation at
37° and 5% CO2. Non-adherent cells were decanted from
the flasks and centrifuged to obtain supernatants. The
flasks were then treated with Enzyme-Free cell dissocia-
tion solution (Specialty Media, Phillipsburg, NJ) and were
gently scraped to remove and harvest cells. Viable cells
from the decanted cells and cell removal mixture were iso-
lated by Ficoll Paque density gradient centrifugation as
above.
Cytokine ELISA
ELISAs (Biosource) were utilized to examine the following
human-specific cytokines: IFN-J, IL-2, IL-4, IL-5, IL-10, IL-
12 p70 and IL-13. All of the ELISAs were performed
according to the manufacturer's instructions. The results
are expressed as pg/ml or ng/ml and all assays were run in
duplicate with at least three separate experiments being
examined.
Real Time PCR
Cytoplasmic RNA was extracted and purified using a com-
mercially available kit (RNAeasy, Qiagen, Valencia, CA).
Purified RNA was electrophoresed on a 1% agarose gel to
assess the integrity of the purified RNA. One Pg of RNA
was reverse transcribed into cDNA using a commercial
available kit (Applied Biosystems, Foster City, CA). One
hundred pg RNA equivalent of this cDNA was used for
PCR amplification. PCR reactions were performed in spe-
cial optical tubes in a 96 well microtiter plate format on
an ABI PRISM 7700 Sequence Detector System (PE
Applied Biosystems) using pre-developed FAM- and
TAMRA-labeled internal oligonucleotide probes and
primers for IL-4 and IL-5 (PE Applied Biosystems). Each
ATRA and an RAR- -D agonist upregulate and an RAR-D antagonist downregulates the ex ssion of IL-4 and IL-5 mRNA  anti-CD3, - ctivat d PBMCFigure 6
ATRA and an RAR- -D agonist upregulate and an 
RAR-D antagonist downregulates the expression of 
IL-4 and IL-5 mRNA in anti-CD3, -activated PBMC. 
Taqman® semi-quantitative PCR for IL-4 and IL-5 transcripts 
was performed using total cellular RNA of 48 h, anti-CD3,-
activated PBMC treated with EtOH, ATRA (10-7 M), an RAR- 
D agonist, AM580 (10-7 M), or an RAR- D antagonist, RO 41–
5254 (10-7 M). Values obtained for each cytokine message 
was normalized to that obtained for 18S rRNA in the same 
sample as described in "Materials and Methods". The normal-
ized values were then expressed as a function of the ETOH 
control sample. The data are representative of all of the 
donors tested.
%0&,PPXQRORJ\ 2008, :16 http://www.biomedcentral.com/1471-2172/9/16
Page 11 of 14
SDJHQXPEHUQRWIRUFLWDWLRQSXUSRVHV
reagent also contains VIC- and TAMRA-labeled internal
oligonucleotide probes and primers specific for the 18S
RNA ribosomal subunit. Amplification conditions were as
follows 25°C for two min; 95°C for 10 min; 40 cycles of
95°C 15 s and 60°C for 1 min. Fluorescence signals meas-
ured during amplification were processed post-amplifica-
tion and were regarded as positive if the fluorescence
intensity was ten fold greater than the standard deviation
of the baseline fluorescence. This level is defined as the
threshold cycle (Ct). The Ct value for18S ribosomal subu-
nit was subtracted from the Ct value for each cytokine
message to normalize for RNA content. This value is
defined as 'CT. To evaluate the effects of retinoids, 'CT-
treatment was subtracted from 'Ctcontrol. This value is
defined as ''CT. The relative folds increase or decrease
was then calculated as 2-''CT.
Flow Cytometric Analysis
Anti-human CD3-FITC (Pharmingen, San Diego, CA),
anti-human CD25-PE, CD38-PE, and, CD69-PE (Becton
Dickinson) were used to assay cell purity and activation
status. Cells (0.25 × 106) were suspended in 50:L of stain-
ing buffer (1% FCS, 1% goat serum, 2.5:g of mouse IgG/
50:L) in round-bottom 96-well plates and incubated at
4°C for 15 min. 5:L of the appropriate dilution of each
antibody was then added to the appropriate wells and
then incubated for 30–40 min at 4°C. After incubation,
the plates were centrifuged and the cells were washed
twice with 100:L of PBS/FBS buffer. After the last wash,
cells were fixed in 100:L of 1% paraformaldehyde solu-
tion in PBS (Electron Microscopy Services, Fort Washing-
ton, PA, in PBS). Samples were subsequently analyzed on
a FACScan flow cytometer (Becton Dickinson) and the
data were processed using the Cellquest program (Becton
Dickinson). A minimum of 10,000-gated events were ana-
lyzed for each sample. Data are expressed as the % of T
cells expressing the marker of interest or the mean chan-
nel number (MCN) of the marker's fluorescent intensity.
Statistical Analysis
To compare the effects of retinoids at various concentra-
tions a two factor ANOVA was performed. Data were first
expressed as percentage of vehicle control culture and
then analyzed for equality of variance using Fisher's F test.
If the variance was heterogeneous, the appropriate trans-
formation of the data was performed. A two factor
ANOVA was used to analyze the effect of retinoid, dose or
any interaction between retinoid and dose. If no signifi-
cant interaction between retinoid and dose was present in
the two-way ANOVA, a Tukey-Kramer post-hoc analysis
was performed to determine statistically significant differ-
ences between each factor level of retinoid and dose. To
examine correlation between the level of T cell activation
and cytokine production, simple regression was per-
Table 4: ATRA and the RAR-D agonist, AM580, directly influence T cell activation and induce T cell differentiation towards a Th2 
phenotype.
A.
Treatment Cytokine (pg/ml) ± SE (n = 4)
IL-4 IL-5 IL-13 IL-10 IFN-J
EtOH Control 77 ± 32 ac 415 ± 188 a 524 ± 249a 491 ± 143 a 4260 ± 674
ATRA 112 ± 48ab 775 ± 328 b 671 ± 280b 295 ± 88 b 4135 ± 379
Am 580 107 ± 34ab 744 ± 307 ab 599 ± 300b 308 ± 94 b 3835 ± 457
RO 41–5253 42 ± 15 c 223 ± 109 c 466 ± 232ac 295 ± 55 b 3230 ± 648
(IL-10, n = 3)
B.
Treatment CD Marker MCN ± SE (n = 3)
CD38 CD69
EtOH Control 466 ± 60 a 348 ± 41a
ATRA 1073 ± 197 b 521 ± 34b
Am 580 1019 ± 151 b 467 ± 18 c
RO 41–5253 296 ± 21 a 263 ± 27 d
T cells were activated for 48 h and cytokines and surface markers were measured as described in the Materials and Methods. Measurements were 
compared with repeated measures ANOVA. Values with different superscripts are significant at p < 0.05. All retinoids were used at a final 
concentration of 1 × 10-7 M.
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formed using activation markers as the independent vari-
able and cytokine levels as the dependent variable. To
evaluate the comparative effects of ATRA, an RAR agonist
and RAR-D antagonist, a repeated measures ANOVA was
used after data were examined for equality of variance as
above. A P < 0.05 was considered statistically significant
for all analysis. All analysis was performed using Statview
5.0 for Macintosh (Abacus Concepts, Berkeley, CA).
List of Abbreviations
ATRA: all-trans retinoic acid; 9-cis RA: 9-cis retinoic acid;
DTH: delayed type hypersensitivity; pTh: precursor T
helper; RARs: retinoic acid receptors; RXRs: retinoid ×
receptors; VA: Vitamin A; 4-HPR: 4-hydroxyphenylretina-
mide; TTNPB: 4- [2-(5,6,7,8-tetrahydro-5, 5,8,8-tetrame-
thyl-2-naphthalenyl)-1-propenyl]benzoic acid; Vit D3: 1,
25 (OH)2 vitamin D3.
The effects of ATRA on Th1 and Th2 cytokine production are primarily mediated through RAR-D with minimal inv lve-m nt of liganded XRsFigu e 8
The effects of ATRA on Th1 and Th2 cytokine pro-
duction are primarily mediated through RAR-D with 
minimal involvement of liganded RXRs. IL-12p70 and 
IFN-J (Panel A) and IL-4 and IL-5 (Panel B) proteins were 
quantitated by ELISA in supernatants of 48 h, anti-CD3,-acti-
vated PBMC treated in the absence or presence of EtOH, 
ATRA (10-8 M), or the RAR-D agonist, AM580 (10-8 M) and in 
the presence or absence of EtOH (&#x25A1;) or the RXR 
agonist (10-8 M, ). The above data are representative of the 
results from two different donors examined.
A RAR- D agonist induces and the RAR- D antagonist, R0 41–5254, reduces the expr sion of CD69 and CD38 on human T cells during activationFigure 7
A RAR- D agonist induces and the RAR- D antagonist, 
R0 41–5254, reduces the expression of CD69 and 
CD38 on human T cells during activation. PBMC were 
activated with anti-CD3, mAb in the presence or absence of 
control ETOH or 10-7 M of ATRA, AM580, or RO41-5254 
for 48 h. After activation, the cells were harvested and the 
cell surface levels of CD69 and CD38 were assessed by flow 
cytometric analysis as described in the Materials and Methods. 
The data are representative of all of the donors tested.
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